Sonnet BioTherapeutics Holdings, Inc. (SONN)
NASDAQ: SONN · Real-Time Price · USD
4.750
-0.140 (-2.86%)
At close: Oct 29, 2025, 4:00 PM EDT
4.960
+0.210 (4.42%)
After-hours: Oct 29, 2025, 6:44 PM EDT
SONN Employees
Sonnet BioTherapeutics Holdings had 13 employees as of September 30, 2024. The number of employees increased by 1 or 8.33% compared to the previous year.
Employees
13
Change (1Y)
1
Growth (1Y)
8.33%
Revenue / Employee
$76,923
Profits / Employee
-$1,042,787
Market Cap
32.43M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 13 | 1 | 8.33% |
| Sep 30, 2023 | 12 | 0 | - |
| Sep 30, 2022 | 12 | 3 | 33.33% |
| Sep 30, 2021 | 9 | 0 | - |
| Sep 30, 2020 | 9 | -21 | -70.00% |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SONN News
- 14 days ago - Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma - GlobeNewsWire
- 5 weeks ago - Sonnet to Present at the MedInvest Biotech & Pharma Conference - GlobeNewsWire
- 2 months ago - Sonnet Releases Virtual Investor "What This Means" Segment - GlobeNewsWire
- 3 months ago - Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer - GlobeNewsWire
- 3 months ago - Why Is Sonnet BioTherapeutics Stock Trading Higher On Monday? - Benzinga
- 3 months ago - Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy - GlobeNewsWire
- 6 months ago - Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit - GlobeNewsWire
- 7 months ago - Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose - GlobeNewsWire